3 completed, 2 recruiting. 3 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Acquired angioedema: new trials by email Literature Review of Acquired angioedema trials Research Report on Acquired angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency Deucrictibant, Placebo - Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | Recruiting | Pharvaris Netherlands B.V. | 48 | 2025-10-16 | 2026-09-21 |
| Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases Usual medical management of patients, additional blood and stool samples for biobanking - Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis | Recruiting | Santé Arménie French-Armenian Research Center | 800 | 2023-06-21 | 2025-04-08 | |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 6 | 2006-11-01 | 2009-05-04 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 3 | Completed | Prothya Biosolutions | 15 | 2006-02-01 | 2009-05-04 |
Angioedema (4) · Angioedemas, Hereditary (2) · Hereditary Angioedema Types I and II (2) · Acquired Immunodeficiency Syndrome (1) · Arthritis (1) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Celiac Disease (1) · Communicable Diseases (1) · Creutzfeldt-Jakob Syndrome (1) · Disseminated Intravascular Coagulation (1) · Giant Cell Arteritis (1) · Hemorrhagic Fever, Ebola (1) · Hepatitis B (1)
Cardiovascular Diseases (5) · Hypersensitivity (5) · Hypersensitivity, Immediate (5) · Immune System Diseases (5) · Skin Diseases (5) · Skin Diseases, Vascular (5) · Skin and Connective Tissue Diseases (5) · Urticaria (5) · Vascular Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Angioedemas, Hereditary (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Digestive System Diseases (2)
Prothya Biosolutions (2) · Albert B. Sabin Vaccine Institute (1) · Pharvaris Netherlands B.V. (1) · Santé Arménie French-Armenian Research Center (1)
Netherlands (3) · United States (2) · Armenia (1) · Australia (1) · Austria (1) · Bulgaria (1) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · New Zealand (1) · Poland (1) · Spain (1) · Switzerland (1)
M. M. Levi, Prof. Dr. (2) · David Hoover, MD (1) · Merry Mazmanian, Dr. (1) · Michael Stevenson, MD (1) · Roxana Rustomjee, MBChB (1) · Tuan Le, MD (1)
PMID 1538192, PMID 15577929, PMID 16375711, PMID 25426834, PMID 8237108